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Abstract. Adrenocortical neoplasms (ACNs) are rare and 
poorly characterized in infants. The true incidence of ACNs 
is not well known and it appears to vary substantially across 
different geographical areas. ACNs are more common in 
females and two peaks of incidence have been identified: The 
first year of life and between the age of nine and 16 years. Due 
to the heterogeneity and rarity of ACNs, their pathological 
and prognostic classification is challenging. The current study 
describes the case of a seven‑year‑old male, who presented 
to the Department of Pediatric Surgery, University of Siena 
(Siena, Italy) with a feminization syndrome and increased 
somatic growth that was associated with a unilateral adrenal 
mass, which was diagnosed by magnetic resonance imaging. 
Surgical excision of the mass was performed and histological 
analysis determined that it was an ACN, with a low risk of 
malignity; however, the pathological classification of the 
tumor was challenging. At present, the future behavior of 
ACNs is unpredictable. Therefore, increasing the knowledge 
surrounding this type of tumor may aid in its diagnosis, treat‑
ment and prognosis. Due to the rarity of pediatric ACNs, no 
single pediatric oncology center has acquired extensive expe‑
rience treating this type of tumor. Thus, the initiation of an 
international tumor registry may aid with the management of 
patients presenting with ACNs.
Introduction
Adrenocortical neoplasms (ACNs) arise from the adrenal 
cortex and are classically considered to be epithelial tumors 
(carcinoma or adenoma) (1). This class of tumors is rare and 
poorly characterized in infants. The tumors exhibit rare clin‑
ical and biological features, which differ from those observed 
in other pediatric carcinomas or the same neoplasms in adults. 
ACNs are more common in females and two peaks of inci‑
dence have been identified, in the first year of life and between 
the age of 9 and 16 years. The manifestations of ACNs are 
dependent on the secretion of adrenocortical hormones by the 
tumor. Cushing's syndrome if the most common manifesta‑
tion, hwoever, feminizing and masculinizing syndromes are 
less common and Conn syndrome, with aldosterone produc‑
tion, is rare. ACNs usually secrete several hormones and thus, 
present the symtpoms of multiple syndromes. Non‑functional 
tumors, which are neoplasms which do not produce adreno‑
cortical hormones, account for ~10% of pediatric cases (1). 
The diagnosis of ACN is challenging and it is determined 
according to the gross and histological appearance of tissue 
samples obtained during surgery (2‑5). Therefore, the role of 
the pediatric surgeon in this type of tumor is considered to be 
significant. The pathological classification of pediatric ACNs is 
difficult and experienced pathologists may find it challenging 
to differentiate between a carcinoma and an adenoma. The 
aim of this report was to describe the case of a seven‑year‑old 
male that presented with an ACN, and to analyze the manage‑
ment of this type of tumor, focusing on the onset, the delay in 
its diagnosis and the difficulties in its histological classifica‑
tion. Written informed consent was obtained from the patient's 
family.
Case report
In September 2012, a seven‑year‑old male was admitted to 
the Department of Pediatric Surgery, University of Siena 
(Siena, Italy) with a feminization syndrome, which presented 
as bilateral gynecomastia. Increased somatic growth was 
observed (bone age was advanced by more than two years) and 
a unilateral adrenal mass was diagnosed by ultrasound (USS). 
The symptoms had begun approximately eight months prior to 
admission, however, the patient had received treatment for an 
endocrinological disease. The patient's plasma testosterone was 
lower than normal (0.57 ng/ml, normal range, 2.7‑10.9 ng/ml) 
and the androstenedione level was within the normal range 
(3.08 ng/ml, normal range, 0.4‑3.1 ng/ml). The plasma estradiol 
level (54.6 pg/ml, normal range, <50 pg/ml) was greater than 
normal. The presence of the mass was confirmed by magnetic 
resonance imaging (MRI), which revealed a unilateral lesion 
of the adrenal gland, measuring ~3.8x2.7x3.2 mm. The lesion 
was well‑defined and no additional abdominal abnormali‑
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ties were present. Furthermore, no lymphadenopathies were 
observed. The results for metanephrines and catecholamines 
obtained from a 24‑h urine test were negative. In addition, a 
computed tomography scan revealed that there was no involve‑
ment of the chest. Surgical excision of the mass was performed 
via an open anterior transperitoneal approach and the entire 
adrenal gland was removed (Fig. 1). A biopsy was performed 
to remove three lymph nodes, as recommended by TREP 
guidelines (4), however, they did not appear to be grossly 
involved. The histological analysis identified that the lymph 
nodes were not involved and determined that the mass was an 
ACN, with a low risk of malignity. There were no complica‑
tions during or post‑surgery, therefore, the postoperative care 
was normal and the patient was discharged on postoperative 
day six. The initial follow‑up was conducted one month 
following surgery, and an abdominal USS and hormone profile 
were performed. The abdominal USS was normal and the 
hormone profile revealed reduced levels of plasma testosterone 
(<0.1 mg/ml, normal range, 2.7‑10.9 ng/ml), androstenedione 
(<0.3 ng/ml, normal range, 0.4‑3.1 ng/ml) and estradiol 
(<20.0 pg/ml, normal range, <50 pg/ml) levels. However, the 
cortisol level (23.6 pg/ml, normal range, 10‑52 pg/ml) was 
normal. The next surgical follow‑ups are expected to be two 
and six months following surgery.
Discussion
The adrenocortical neoplasm (ACN) is a rare type of pediatric 
tumor and represents <0.5% of all childhood neoplasms and 
6% of all pediatric adrenal tumors (1,3‑5). The true incidence 
of these tumors is not well known and it appears to vary 
substantially across geographical areas. In the USA, ~10,000 
new cases of ACN are diagnosed annually in patients aged 
<20 years (1). In Southern Brazil (São Paulo and Parana), 
however, the incidence is approximately >10 times this (1); 
however, the cause of this increased rate has not been iden‑
tified. Furthermore, this type of tumor is more common in 
females, although the reason for this remains unknown (6). 
Two peaks of incidence of ACN have been identified: The 
first year of life and between the ages of nine and 16 years. 
Predisposing inherent genetic factors have also been identified 
in ~50% of infants exhibiting ACNs. Furthermore, two genetic 
syndromes, Li‑Fraumeni and Beckwith Wiedemann (7‑9), are 
associated with these tumors and its frequency of presentation 
in individuals with these syndromes is >100 times that of the 
general population (7). Additionally, the association between 
ACNs and environmental factors, such as prenatal exposure 
to carcinogens or fetal alcohol syndrome, has been reported 
in previous studies, however, was difficult to verify as these 
factors may also be associated with other neoplasms (11,12). 
The patient described in the current report was a seven‑year‑old 
Italian male, without any associated syndrome or antenatal 
history of exposure to carcinogenic factors. The patient was 
admitted to the Department of Pediatric Surgery eight months 
following the onset of symptoms of bilateral gynecomastia 
(indicating a feminization syndrome) and increased somatic 
growth. Initially, the patient received treatment for an endo‑
crinological disease, and only following an USS that revealed 
the adrenal mass, was the patient referred to the Department of 
Pediatric Surgery. This is consistent with previously reported 
cases that describe the secretion of adrenocortical hormones 
by the tumor as the initial manifestation of the presentation 
of ACNs (13‑15). Cushing's syndrome is the most frequent 
symptom of raised hormone levels; however, the feminizing 
and masculinizing syndromes are less common and present 
as the initial manifestation of ACN in only 2.2% of cases (16). 
Furthermorem, Conn's syndrome, which produces aldosterone, 
is rare. However, although the clinical manifestations of one 
endocrine syndrome may predominate, ACNs often secrete a 
variety of hormones and, thus, present the signs and symptoms 
of multiple syndromes (mixed forms).
Non‑functional tumors comprise ~10% of pediatric cases, 
worldwide. However, a significant clinical manifestation that 
is observed in patients with functioning ACNs, and androgen 
and estrogen overproduction, is growth disturbance in terms of 
overgrowth. Generally, an infant exhibiting this condition pres‑
ents with increased somatic growth for their chronological age, 
however, are generally healthy. This clinical effect is described 
by numerous studies (13‑15). Hauffa et al (15), demonstrated 
increased growth in 10 infants aged 0.8‑11.8 years who exhib‑
ited adrenocortical tumors and hormone overproduction. The 
implications of recognizing this as a symptom of ACN are 
significant, and may facilitate the early diagnosis of the tumor 
prior to the onset of other tumor‑associated symptoms, and 
increase the possibility of avoiding long‑term effects on final 
adult height (although it is currently unclear if these factors 
are correlated).
Due to the rarity of pediatric ACNs, the majority of pedi‑
atric onoclogy centers have reported observations of only 
a small number of patients over several years and there are 
few multicenter, long‑duration studies with a large series. 
Lefevre et al (16) reported 42 infants treated in various French 
hospitals over a 22‑year period. Ribeiro et al (17‑19) reported 
the results of infants with ACNs treated at a single institution in 
Southern Brazil over a duration of ~10 years. In another study, 
Liou and Kay (20) summarized the results of 412 patients from 
a variety of published series, predominantly from the USA. 
Michalkiewicz et al (3), provided a descriptive analysis of 
254 patients that were registered on the International Pediatric 
Adrenocortical Tumor Registry (3). The current study followed 
the guidelines proposed by TREP to determine the diagnostic 
procedures and treatment management (4). These guidelines 
were developed by an Italian research group that aim to estab‑
lish guidelines for the diagnosis and treatment of rare types of 
pediatric tumor. The diagnosis in the current study was deter‑
Figure 1. Intraoperative image of the excised tumor.
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mined by abdominal USS and MRI, in addition to conducting 
a complete hormone profile (as recommended by the TREP 
guidelines). The role of the pediatric surgeon is particularly 
significant in the pathology of ACNs and surgical management 
must be considered for all cases of childhood ACN, although 
the optimum treatment strategy remains unknown. The litera‑
ture surrounding the treatment of pediatric ACN cases is poor, 
while it is well clarified in adult patients (18). However, there 
is currently no gold standard approach. Numerous studies have 
proposed open transperitoneal resection as it is associated with 
a decreased risk of bleeding, improved visualization of the 
tumor boundaries and it allows for the inspection and biopsy 
of the contralateral adrenal and adjacent lymph nodes (1,2,4). 
Thus, an open transperitoneal resection was conducted in 
the present case. However, as described by Cobb et al (21) a 
laparoscopic approach (via a transperitoneal or retroperitoneal 
route) may be an alternative option for a highly experienced 
surgeon treating older patients (>13 years) that present with 
a low probability of malignancy and small tumors (<6 cm). 
It is evident that determination of the surgical approach is 
influenced by the surgeon's experience, however, irrespective 
of the type of surgery, all surgeons must endeavor to achieve 
complete removal of the tumor, potentially at the expense of 
adjacent structures, and perform a regional lymph node biopsy 
(even when lymph node involvement is not apparent).
The histological features of this type of tumor remain 
controversial. The pathologist usually determines the 
definitive diagnosis and prognosis of the tumor; however, 
in pediatric adenocarcinoma, the role of the pathologist is 
different. Due to the rarity of pediatric ACN, the experience 
of patholgists is limited and thus, it is difficult for patholo‑
gists to establish a diagnosis. The histological features are 
not considered to be markers of malignancy in infants, and 
due to the heterogeneity and rarity of ACNs, the prognostic 
factors have been difficult to establish. Prognostic factors are 
based on the TREP pathway, which includes the following: 
The radicality of exeresis; the presence of metastasis; the 
weight of the mass, which is considered to be the predomi‑
nant prognostic element (cut off, <150 g); the duration of 
symptoms (cut off, six months); age of the infant (<3 years 
indicates improved prognosis); and histological features (4). 
The survival rate of ACNs is between 15 and 70%. However, 
prognosis is dependent on numerous factors. A young patient 
(<3 years), presenting with symptoms within six months 
of onset, exhibiting a small mass (<150 g) who receives an 
open complete resection, and demonstrates negative results 
from histological analysis of the lymph nodes and does 
not exhibit metastasis is a typical case with an optimal 
prognosis. Notably, pediatric adrenal tumors are associated 
with an improved prognosis when compared with the same 
masses in adults. The staging of ACN in infants varies from 
that used for adults and it is based on the size of the mass, 
the evidence of invasion or regional/distant metastasis, 
the radical removal of the tumor and the normalization of 
hormone levels following surgery (5,18,23). The patient in the 
current study had a stage 1 ACN (4). However, the risk strati‑
fication system, which was developed to guide physicians in 
treatment planning, is considered to be more important than 
tumor staging. The risk groups are based upon the success 
of the administered treatment and the survival rates. Patients 
are assigned to one of the three groups: Low, intermediate or 
high risk (18). In the current study, the patient was assigned 
to the low risk group. The benefit of risk grouping is that 
it provides the patient with the optimal treatment plan, 
while minimizing the requirement for toxic therapies. As 
described in the TREP guidelines, the postoperative evalua‑
tion involves USS or MRI of the site of the excised tumor and 
hormone profiling (4), which were conducted for the current 
patient two weeks following surgery and exhibited negative 
results. The future follow‑up, which will comprise the same 
analysis, will be performed at two‑month intervals for the 
initial two years, at three‑month intervals in the third year, at 
four‑month intervals in the fourth year and annually from the 
fifth year onwards. However, the infant in the present case 
was referred to the Department of Oncology to manage the 
medical aspects of the pathology.
In conclusion, the current report may be beneficial in 
increasing the knowledge of ACNs. The present case of ACN 
in an infant male was managed according to the TREP guide‑
lines; however, an international tumor registry is proposed 
as it may aid with the consistent management of these types 
of patient worldwide. Furthermore, the present report aimed 
to highlight the important role of pediatric surgeons, who 
are required within the team that manages the pathological 
analysis of ACNs in infants. Additionally, we described the 
marginal role that pathologists have had in previous cases, 
which explains the challenges experienced by the pathologist 
involved in the present case in diagnosing this type of tumor.
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